about
Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell LinesPARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastomaGankyrin Drives Malignant Transformation of Gastric Cancer and Alleviates Oxidative Stress via mTORC1 Activation
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Gankyrin as a potential therapeutic target for cancer.
@en
Gankyrin as a potential therapeutic target for cancer.
@nl
type
label
Gankyrin as a potential therapeutic target for cancer.
@en
Gankyrin as a potential therapeutic target for cancer.
@nl
prefLabel
Gankyrin as a potential therapeutic target for cancer.
@en
Gankyrin as a potential therapeutic target for cancer.
@nl
P2860
P1476
Gankyrin as a potential therapeutic target for cancer.
@en
P2093
Chongchong Wang
P2860
P2888
P356
10.1007/S10637-017-0474-8
P577
2017-05-19T00:00:00Z